Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms

Published:2011-04 Issue:4 Volume:35 Page:459-464
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Spanoudakis Emmanouil,Bazdiara Ioanna,Pantelidou Despoina,Kotsianidis Ioannis,Papadopoulos Vasilios,Margaritis Dimitrios,Xanthopoulidis George,Moustakidis Eleftherios,Mantzourani Stamatia,Bourikas George,Tsatalas Costas

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference40 articles.

1. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice;Hande;J Cell Biol,1999

2. Telomeres, stem cells, and hematology;Lansdorp;Blood,2008

3. Repair of telomeric DNA prior to replicative senescence;Lansdorp;Mech Ageing Dev,2000

4. Telomere dysfunction and the initiation of genome instability;Feldser;Nat Rev Cancer,2003

5. Telomere dysfunction increases mutation rate and genomic instability;Hackett;Cell,2001

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling;Frontiers in Oncology;2023-10-24

2. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms;2023-09-12

3. Telomerase-targeted therapies in myeloid malignancies;Blood Advances;2023-08-09

4. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design;Future Oncology;2022-07

5. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN;International Review of Cell and Molecular Biology;2022